Targets › SSTR
3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: the race on SSTR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Lu-DOTA-TATE Somatostatin receptor agonist radiopharmaceutical (Lutetium-177 octreotate) | SSTR | Phase 2 | Neuroendocrine Carcinoma | Dec 2027 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Al18F-octreotide Somatostatin receptor (SSTR) imaging agent; Al18F-labeled octreotide for PET/CT imaging | SSTR | Phase 2 | SSTR Positive Tumors | Dec 2028 |
| ITM Solucin | Lutetium Lu 177 Edotreotide SSTR-targeting radiopharmaceutical therapy delivering Lu-177 radiation | SSTR | Phase 1 | Somatostatin Receptor Positive | Jun 2028 |
Neuroendocrine Carcinoma (1) Somatostatin Receptor Positive (1) SSTR Positive Tumors (1)
protein or peptide (2)
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) ITM Solucin (1) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.